Abstract
Immune checkpoints inhibitors (ipilimumab, nivolumab, pembrolizumab, cemiplimab, atezolizumab, avelumab, durvalumab) are monoclonal antibodies that target cell membrane receptors (CTLA-4, PD-1, PDL-1) implicated in the immunosuppression. This results in activation of the lymphocytic immune response leading to CD8+ T cells proliferation in many organs including the heart. However, the management consists of stopping the immunotherapy and starting high-dose corticosteroids. The incidence of these toxicities as well as their pathophysiology, risk factors, onset and prognosis are not clearly established yet due to the lack of data and cohort studies. Despite the FDA approval of these drugs in the treatment of many refractory cancers, they should be used with caution due to their devastating repercussions.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Cardiology Research Reviews & Reports
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
